PDB10 Economic Evaluation of Duloxetine as First-Line Treatment for Painful Diabetic peripheral Neuropathy in Mexico  by Carlos, F. et al.
OBJECTIVES: Estimate the effects on glycosylated hemoglobin (HbA1c) and the ac-
cumulated cost of treatment of the use and provision of various self-monitoring of
blood glucose (SMBG) regimes plus conventional pharmacologic treatment on
type-2 diabetic (T2D) patients from the Mexican public health system perspective.
METHODS: The individual experience of a T2D patient was simulated using a dis-
crete event simulation (Arena™). Patients were created with unique, randomly
assigned baseline characteristics, cloned three times and sent to each of the con-
sidered SMBG regimes (0, 1, 2 and 3 times daily). T2D- and complication-related
pharmacologic treatment & resource utilization, and treatment algorithms and
goals were based on published clinical guidelines. Treatment therapies included
lifestyle modifications alone, oral antidiabetics (OADs) and insulin use. HbA1c was
the main driver of disease progression, determining initial state, clinical evolution
and drug/insulin dosages. Complication and acute event development for each
SMBG regime was assessed through published local relative risk studies. Consid-
ered OADs and insulin types were assumed equally effective. Clinical and cost data
were obtained from published literature. Mortality was assessed by disease dura-
tion. Simulation was run with 250,000 patients for 10 years using a 4.5% annual
discount rate. Average per-patient costs are shown in inflation-adjusted 2011 MXP.
RESULTS: More intensive SMBG regimes resulted in lower final average HbA1c
levels; 1, 2 and 3 times daily SMBG regimes resulted in lesser costs than no SMBG
after years 3, 3 and 4, respectively. Year-10 accumulated costs for the former were
$598,189, $590,616 and $589,008, and $614,162 for no SMBG. Savings are due to
fewer complications and slower disease progression under any SMBG regime.
CONCLUSIONS: As more intensive SMBG regimes result in lower HbA1c levels and
treatment costs, glycemic control should be an objective of every T2D integral
treatment strategy, potentially reducing the social and economic burden imposed
by the disease.
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IMPROVE CLINICAL AND METABOLIC OUTCOMES AND OPTIMIZE THE USE OF
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OBJECTIVES: To evaluate the efficacy of educational interventions in the
PRODIACOR study and estimate pharmacological treatment costs. METHODS:
PRODIACOR is a 3-year prospective and randomized controlled trial, aimed at im-
proving the quality of care of people with type 2 diabetes, preventing complications
and optimizing resource use. It includes 4 groups (control, educated patients, ed-
ucated physicians and educated patients and physicians) with 9 physicians and
117 patients each. Clinical and metabolic changes were recorded in ad-hoc forms
(annual and semiannual). Costs and utilization rates were obtained from the ad-
ministrative dataset of the coverage institutions involved. We verified differences
in means and proportions using ANOVA and Chi2.RESULTS:After the 3-year follow
up we recorded significant improvements (p0.001) in all groups in systolic blood
pressure (14217 vs. 13415 mmHg), HbA1c (7.81.5 vs. 7.10.8%) and total cho-
lesterol (4.70.9 vs. 4.40.7 mmol/L). All these changes were significantly larger in
the intervention groups. The percentage of patients at target for all these param-
eters was significantly larger (p0.01) in these groups. In the educated groups, we
also recorded a significant increment in combined against oral monotheraphy (42
vs. 30%) and insulin use (15 vs. 9%). Drug consumption and strips for blood glucose
represented 64 and 83% of the total care cost at baseline and 3-year follow up,
respectively. This cost increased (113%) in the control group while it significantly
decreased (11 to 20%) in the intervention groups, particularly in the patient/physi-
cian educated group. The cost to decrease HbA1c by 1% or SBP by 10 mmHg in the
patient/physician educated group was lower than in the control group ($161 vs.
$547, $16 vs. $77, respectively). CONCLUSIONS: Educational interventions imple-
mented at primary care level improved the clinical and metabolic outcomes of
people with Type 2 diabetes and optimized the use of resources.
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OBJECTIVES: To evaluate the economic consequences of saxagliptin (SAXA) versus
sulfonylurea (SU) administration in combination with metformin (MET) after fail-
ure of MET monotherapy treatment, in patients with type 2 diabetes (T2DM).
METHODS: A discrete event simulation model (Cardiff Long term cost-utility
model) based on UKPDS 68 with a fixed time increase was used to simulate disease
progression and to obtain an estimate of the treatment’s economic and health
consequences in patients with T2DM from Argentina, Chile and Peru. The clinical
efficacy parameters for SAXA were obtained from the literature; drug acquisition
costs, adverse effects (AEs) and microvascular and macrovascular complications
were obtained from local studies. Costs were expressed in US dollars (2009), with an
annual 3.5% discount. The time horizon was 20 years. RESULTS: In all countries,
the number of non-fatal events was lower in the SAXAMET group than in the
SULFMET group. The model also predicted a lower number of fatal macrovascular
and microvascular events for the SAXAMET-treated group. In Argentina and Perú,
the total cost of the SAXAMET cohort was higher than that of the SULFMET
cohort (14% and 3%, respectively), while in Chile the total cost of the SAXAMET
cohort was 3% lower than that of the SULFMET. Treatment with SAXAMET
resulted in a higher number of QALYs (Argentina: 9,392 vs. 9,172; Chile: 9,794 vs.
9,594; Peru: 9,796 vs. 9,597) and LYGs (Argentina: 20,898 vs. 20,797; Chile: 23,068 vs.
23,019; Peru: 23,079 vs. 23,028) as compared with SULFMET. The additional cost
per QALY was U$S6,691, U$S2,446 and -U$S2,243 for Argentina, Peru and Chile,
respectively. CONCLUSIONS: Considering the GDP per capita in Argentina and Peru,
the addition of SAXA instead of SU to MET therapy would result in acceptable
cost-effectiveness ratios in T2DM patients, being this combination cost-saving
(dominant cost-effectiveness ratio) in Chile.
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OUTPATIENTS DIAGNOSED WITH TYPE-2 DIABETES ATTENDING A PRIMARY
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OBJECTIVES: To assess the cost-effectiveness (CE) ratios of oral hypoglycemic
agents (OHA’s) most used (acarbose, metformin and glyburide) on the initial phar-
macologic therapy of outpatients diagnosed with type 2 diabetes in a primary care
public clinic in Mexico City. METHODS: We conducted a cost-effectiveness study
based on a Markov model during a time horizon of one year and from the perspec-
tive of the Mexican society. The model designed included two health states (HbA1c
 7% and HbA1c 7%) and 6 months for the evaluation of monotherapy with OHA’s
and 6 months for the addition of a second OHA in case of failure of the first (met-
formin - glyburide dual therapy) were considered. We assessed the total monthly
costs of the treatments with the OHA’s through a structured questionnaire applied
to 27 outpatients recently diagnosed with type 2 diabetes in treatment in a primary
care public clinic in Mexico City during 2009. The efficacies (treatments success
probabilities if HbA1c  7% was reached) as well adverse events frequencies were
assessed through a systematic review of published randomized clinical trials and
meta-analysis of selected studies based on structured inclusion criteria. We used a
commercial computational program to perform the cost-effectiveness analysis for
a hypothetical cohort of 10,000 patients through a Monte Carlo simulation and an
univariate sensibility analysis was performed. RESULTS: The CE ratios found were
glyburide US$ 272.63/QALY, metformin US$ 246.48/QUALY and acarbose US$
409.86/QALY. Acarbose and metformin showed high frequency of gastrointestinal
adverse events (78% and 54% respectively), and glyburide showed mainly hypogly-
cemia (31%). The sensitivity analysis did not show changes for the most CE therapy
when the success probabilities or the treatment costs were modified.
CONCLUSIONS: Initial monotherapy with glyburide offers the best cost-effective-
ness ratio.
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OBJECTIVOS: Analizar la relación costo-efectividad del uso de Detemir frente a
otras insulinas (Glargine e insulina NPH) para tratamiento de diabetes tipo 2 en
Colombia. METODOLOGÍAS: Mediante un modelo probabilístico de Markov se re-
alizó un análisis de costo-efectividad, desde la perspectiva del tercero pagador, en
un horizonte temporal de 5 años en una cohorte de 10,000 personas con edad media
de 45 años. Como desenlaces se evaluaron eventos cardiovasculares y muertes
evitadas, relacionadas con eventos de hipoglicemia severa y Años de Vida Salvados
(AVS). Se utilizaron los IC de las probabilidades de los desenlaces evaluados obteni-
das de la revisión de estudios clínicos. Los costos se extrajeron de bases de datos de
prestadores de servicios de salud en Colombia, a precios 2010. Se utilizó una tasa de
descuento del 3% para costos y resultados. Se realizó un análisis de sensibilidad
tipo montecarlo con 1000 iteraciones para probar la solidez de los resultados.
RESULTADOS: En un horizonte temporal de 5 años el Detemir presentó un menor
número de eventos de hipoglicemia severa (730) frente a Glargine y NPH (1910 y
2140) respectivamente, a su vez menor número de eventos macrovasculares (1052)
y microvasculares (1019) frente a Glargine (1115, 1040) y NPH (1130 y 1042). Detemir
evitó 112 y 131 muertes frente a Glargine y NPH equivalentes a 3935 y 3363 AVS
respectivamente. Luego del descuento el ICER por AVS con Detemir frente a
Glargine fue de 1043 USD y frente a NPH 8795.5 USD. En el análisis de sensibilidad
Detemir se mantiene costo-efectivo en el 100% de los casos por debajo del umbral
de costo efectividad frente a los comparadores, tomando como umbral lo
propuesto por la OMS. CONCLUSIONES: Detemir, desde la perspectiva del tercer
pagador, es costo-efectivo frente a Glargine y NPH para tratamiento de diabetes
tipo 2 en Colombia.
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ECONOMIC EVALUATION OF DULOXETINE AS FIRST-LINE TREATMENT FOR
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Carlos F1, Ramírez-Gámez J2, Dueñas-Tentori H2, Ramos E1
1R A C Salud Consultores, S.A. de C.V., México D.F., México, 2Eli Lilly and Company, México D.F.,
México
OBJECTIVES: To perform an economic evaluation of duloxetine, pregabalin and
(either branded or generic) gabapentin for managing pain in patients with painful
diabetic peripheral neuropathy (PDPN) in Mexico. METHODS: The analysis was
conducted using a three-month decision model, which compares duloxetine 60mg
once daily (DUL), pregabalin 150mg twice daily (PGB) and gabapentin 600mg three-
times daily (GBP) for patients with PDPN and moderate-to-severe pain, under the
perspective of the Mexican public health care system. We performed a systemic
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review and calculated placebo-adjusted risk ratios for achieving good pain relief
(GPR), any adverse event (AE) and withdrawal owing to intolerable AE. Direct med-
ical costs included drug acquisition and additional visits due to lack of efficacy
(poor pain relief) or intolerable AE. Unit costs were taken from local sources. Ad-
herence rates (based in number of daily doses needed) were used to estimate the
expected drug costs. All costs are expressed in 2010 USD (1USD:12.50MXN Pesos).
Utility values drawn from published literature were applied to health states. Pro-
portion of patients with GPR and quality-adjusted life years (QALY) were assessed.
RESULTS: Branded-GBP was dominated by all the other options. PGB was more
costly and less effective than DUL. Compared with branded-GBP and PGB, DUL led
to savings of $80,080 and $85,920 (per 1000 patients) USD. The incremental cost per
QALY gained with DUL used instead of generic-GBP was $8,194. This amount is
slightly lower than the estimated gross domestic product per capita in Mexico for
2010. During a second-order Monte Carlo simulation, DUL had the highest proba-
bility of being cost-effective (61%), followed by generic-GBP (25%) and PGB (14%).
CONCLUSIONS: This study suggests that DUL provides overall savings and better
health outcomes compared with branded-GBP and PGB. Administering DUL rather
than generic-GBP is a highly cost-effective intervention to manage PDPN in Mexico.
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OBJECTIVES: Fragility fractures (FF) are associated with increased mortality, dete-
rioration in health-related quality of life and high costs. Teriparatide stimulates
bone remodeling. The aim of this study was to assess the cost and health effects of
teriparatide in women with postmenopausal osteoporosis (PMOP) and high risk of
FF from the perspective of public healthcare system in Mexico. METHODS: Target
population was women aged 70 years, with PMOP, T-score 4.0 and three clinical
risk factors, with a recent vertebral fracture not candidates to receive bisphospho-
nates. Competing alternatives were: (1) daily subcutaneous injection of teripa-
ratide 20mcg for 18 months and (2) no therapy. A Markov microsimulation model
was developed with a 30 years time horizon divided into 6-month cycles and is
composed by 5 health states: hip, vertebral, forearm and humerus fracture and
death. The incidence of FF was obtained from the FRAX® algorithms for Mexican
women. Efficacy data was gathered from placebo-controlled clinical trials of teripa-
ratide. We analyzed acquisition costs of teriparatide and medical care costs due to
FF. Frequency and location of fractures avoided and quality adjusted life years
(QALYs) were estimated. All costs are expressed in 2010 USD (1USD:12.50MXN
Pesos) RESULTS: Teriparatide avoided 324 FF per a thousand patients (hip: 43;
vertebral: 164; humerus: 35; forearm: 82). The number needed to treat (NNT) to
prevent one FF was 3.09. Teriparatide was slightly more expensive ($20,052 vs.
$22,209 USD) but more effective, with net gains of 87 QALYs per a thousand pa-
tients. The cost per additional QALY gained with teriparatide was $24,925 (below
the upper limit of 3 times the gross domestic product per capita in Mexico). Teripa-
ratide was found to be cost-effective therapy in 80% of the simulations performed
in the probabilistic sensitivity analysis. CONCLUSIONS: Teriparatide is a cost-ef-
fective intervention in women with PMOP and high risk of FF.
Gastrointestinal Disorders – Cost Studies
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OBJECTIVES: To assess health care resources use and costs associated with man-
agement of complex perianal fistula in Crohn’s disease (CPCD) in Spain.METHODS:
Multicenter, retrospective and observational study conducted by 13 gastroenterol-
ogists from 11 hospitals in the Autonomous Community of Madrid, Spain. Direct
healthcare resources consumption (pharmacological treatments, laboratory/diag-
nostic tests, visits to specialists, emergency department visits and hospitaliza-
tions/surgical procedures) were recorded for 97 adult patients with CPCD active at
some time between January 1, 2005 and study data collection (4.21.5 years).
RESULTS: 527 treatments were recorded: 73.1% pharmacological (32.3% antibiotics,
20.5% immunomodulators, 20.3% biological therapies) and 26.9% surgical. Mean
per patient-year global cost was €7821.4. Percentage cost per treatment type and
[mean per patient-year cost] breakdown was 78.7% [€5773.5] pharmacological cost,
11.12% [€1027.4] hospitalizations/surgical procedures, 6.5% [€640] specialists visits,
3.4 [€350] laboratory/diagnostic tests, and 0.2%, [€30.4] emergency department vis-
its. Mean per patient-year cost per pharmacological treatment type was: €12.5
antibiotics, €1050.6 immunomodulators, and €4710.4 biological therapies.
CONCLUSIONS: Pharmacological treatments are the main cost driver of CPCD
management in Spain, being biological therapies the main component. Study
funded by Cellerix, S.A. (Spain).
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OBJECTIVES: To estimate the cost-effectiveness of adalimumab CD treatment ver-
sus standard care and infliximab for patients with severe active CD. METHODS:
The model combines clinical, utility, and cost data. Four disease states (remission;
moderate; severe; very severe) based on the Crohn’s Disease Activity Index range
are used as measures of patient disease status. For the adalimumab arm, a cohort
for the proposed adalimumab regimen using actual observations from the EOW
arm in a randomized controlled clinical trial (CHARM) is used. For the standard care
arm, the model simulates patient disease states based on randomized controlled
trial data (CLASSIC I and CHARM) and calculates the probability of individuals
being in each disease state. The base-case model analyzes lifetime patient clinical
status. Hospitalization costs are estimated from the hospitalization unit cost and a
regression model based on CHARM trial data. Disease state specific non-hospital-
ization, non-anti TNF costs are summarized over time for each patient to include
other direct medical costs. For the adalimumab vs. infliximab model, the adali-
mumab regimen is compared to infliximab 5mg/kg maintenance therapy. The per-
centage of patients in remission over time is used as the measure of clinical effi-
cacy. Indirect costs are estimated based on hospitalization stays and post-
hospitalization recovery times. Costs are reported in Mexican Peso. RESULTS:
Compared to standard care, adalimumab is dominant for patients with severe CD
(cost difference -$16,825, gain in QALYs 0.1045). Adalimumab is dominant, with
lower costs and higher efficacy compared with infliximab when treating patients
with severe disease based on a societal perspective. Cost difference (adalimumab–
infliximab) were -$19,784, and including infliximab “overdosing”, the costs ac-
counted for -$42,356. Sensitivity analyses confirm the results obtained in the cost-
effectiveness analysis. CONCLUSIONS: Adalimumab maintenance therapy is
dominant over standard care. The adalimumab regimen is cost-saving over inflix-
imab 5mg/kg maintenance therapy.
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OBJECTIVOS: Mediante la adaptación a la realidad de Venezuela de un modelo
realizado por Spackman y Veenstra y previo análisis de transferibilidad, se realizó
un análisis de costo-efectividad del uso de 0.5 mg/día de entecavir versus inter-
ferón pegilado en la supresión de la replicación viral y la calidad de vida relacio-
nada con la salud en términos de QALYs en pacientes con Hepatitis B Crónica.
METODOLOGÍAS: Para la construcción de la cohorte hipotética, Spackman y Veen-
stra asumieron los datos de las eficacias así como las características de los pacien-
tes reportadas en estudios clínicos recientes. Para el análisis de transferibilidad se
siguieron los criterios de transferibilidad de la Task Force on Good Research Prac-
tices on Transferability of Economic Data de la ISPOR. En la adaptación del modelo
se asumieron las probabilidades de cambio entre estados reportadas en el estudio
original. Los costos médicos directos y de los medicamentos fueron tomados di-
rectamente del entorno local. Adicionalmente se tomaron las tablas de expectativa
de vida del observatorio de salud global de la Organización Mundial de la Salud para
Venezuela actualizadas al año 2008. Los resultados incluyeron los costos de cada
alternativa de tratamiento tanto con entecavir como con interferón pegilado, así
como los años de vida ajustados a calidad ganados. RESULTADOS: El entecavir 0.5
mg/día produjo 18,25 QALYs y una relación de costo efectividad media de 5.257 BsF
por QALY, en comparación con el interferón pegilado (marketshare) que produjo
18,12 QALYs y una relación de costo efectividad media de 7.055 BsF por QALY.
CONCLUSIONES: El entecavir a dosis de 0.5 mg/día mostró índices más bajos de
costo-efectividad media con respecto al interferón pegilado en la supresión viral en
pacientes con infección por el virus de la hepatitis B. En Venezuela, al igual que
muchos países latinoamericanos, no están establecidos umbrales de costo efectivi-
dad.
Gastrointestinal Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS IN PATIENTS WITH
ACTIVE CROHN’S DISEASE FOLLOWING TREATMENT WITH CERTOLIZUMAB
PEGOL IN THE MUSIC STUDY (NCT00297648)
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1Centre Hospitalier Universitaire de Nice, Nice, France, 2Hôpital Saint-Louis, Paris, France, 3UCB,
Braine l’Alleud, Belgium, 4Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
OBJECTIVES: MUSIC, an open-label, 1-year study of certolizumab pegol (CZP), eval-
uated the efficacy of CZP in improving pathological changes in the intestinal mu-
cosa of patients with active moderate-to-severe Crohn’s disease (CD). The purpose
of this posthoc study was to examine the relationship between CZP-mediated en-
doscopic improvement and changes in HRQoL in patients with CD. METHODS:
Patients with active CD (CD Activity Index score 225 to 450) were treated with
open-label CZP, 400 mg subcutaneously every 2 weeks for 3 doses (induction) then
400 mg every 4 weeks for up to 54 weeks (maintenance). Patients completed the
Inflammatory Bowel Disease Questionnaire (IBDQ) at baseline, Week 10, and Week
54 to assess HRQoL. An exploratory analysis of the correlation between IBDQ re-
mission (total score 170 points) and endoscopic remission (measured by a CD
Endoscopic Index of Severity score of 6 points) was performed. RESULTS: Of 89
patients entering the study, 78 patients at Week 10 and 50 patients at Week 54
completed the IBDQ. At baseline, mean IBDQ total score was 120.2. At Week 10,
mean change in IBDQ total score was 43.8 and the IBDQ remission rate was 43.8%.
At Week 54, mean change in IBDQ total score was 44.1 and the IBDQ remission rate
A548 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 5 3 5 - A 5 7 0
